Watch SPRO. Know when insiders buy.
One email the day a filing lands. Free.
SPRO
Spero Therapeutics, Inc.
1.18
−0.05 −3.66%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
99
PASS · shorts 99
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $69MP/E 8.5DIV YIELD —FCF YIELD —REV TTM $47M −3.3%NET INCOME $7.4MNET CASH —52W 1.11 – 2.98SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$9.9M | −$9.6M | — | -0.16 | −$5.4M | — | — | Aug 12 |
| Q1 2026 · Mar 31 | $258K | −95.6% | — | −$7.5M | −$7.2M | — | -0.13 | $15.9M | — | — | May 13 |
| Q4 2025 · Dec 31derived | $41.3M | +174.5% | — | $31.4M | $31.5M | — | 0.56 | −$8.4M | — | — | Mar 26 |
| Q3 2025 · Sep 30 | $5.4M | −59.6% | — | −$7.9M | −$7.4M | — | -0.13 | $17.4M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | $14.2M | +39.1% | — | −$2.4M | −$1.7M | — | -0.03 | −$17.7M | — | — | Aug 12 |
| Q1 2025 · Mar 31 | $5.9M | −36.6% | — | −$14.7M | −$13.9M | — | -0.25 | −$4M | — | — | May 13 |
| Q4 2024 · Dec 31derived | $15M | −79.5% | — | −$21.7M | −$20.9M | −140.8% | -0.38 | −$23.4M | — | — | Mar 26 |
| Q3 2024 · Sep 30 | $13.5M | −47.1% | — | −$18.6M | −$17.1M | — | -0.32 | $12.8M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | $10.2M | — | — | −$19.1M | −$17.9M | — | -0.33 | −$18.7M | — | — | Aug 12 |
| Q1 2024 · Mar 31 | $9.3M | — | — | −$14M | −$12.7M | — | -0.24 | $5.9M | — | — | May 13 |
| Q4 2023 · Dec 31derived | $73.5M | — | — | $50.5M | $51.2M | — | 0.97 | −$17.5M | — | — | Mar 27 |
| Q3 2023 · Sep 30 | $25.5M | — | — | −$1.9M | −$3.2M | — | -0.06 | $15.9M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $66.8M | — | $6.3M | $8.6M | 12.8% | 0.15 | −$12.6M | — | — | — | — |
| FY2024 · to Dec 31 | $48M | — | −$73.4M | −$68.6M | -142.9% | -1.27 | −$23.4M | — | — | — | — |
| FY2023 · to Dec 31 | $103.8M | — | $21.5M | $22.8M | 22.0% | 0.43 | −$33M | — | — | — | — |
| FY2022 · to Dec 31 | $53.5M | — | −$42.2M | −$46.4M | -86.7% | -1.23 | −$7.7M | — | — | — | — |
| FY2021 · to Dec 31 | $18.3M | — | −$88M | −$89.8M | -491.9% | -2.91 | −$64.3M | — | — | — | — |
| FY2020 · to Dec 31 | $9.3M | — | −$79.1M | −$78.3M | -839.2% | -3.52 | −$85.9M | $157K | −$86M | — | — |
Every number comes from Spero Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.